Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of DA-8010 with Clarithromycin and Rifampicin
NCT05991401Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Aug 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of velufenacin in overactive bladder (OAB), sponsored by Dong-A ST. Primary endpoints: Peak Plasma Concentration of DA-8010 and Area under the plasma concentration versus time curve of DA-8010. Started Aug 2023; status: completed.
02
Drugs
velufenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT05991401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05991401.